The role of radiation therapy in melanoma.
Identifieur interne : 001302 ( PubMed/Curation ); précédent : 001301; suivant : 001303The role of radiation therapy in melanoma.
Auteurs : Jacqueline Oxenberg [États-Unis] ; John M. Kane [États-Unis]Source :
- The Surgical clinics of North America [ 1558-3171 ] ; 2014.
Descripteurs français
- KwdFr :
- Antinéoplasiques (usage thérapeutique), Facteurs de risque, Humains, Interférons (usage thérapeutique), Lymphadénectomie, Mélanome (), Mélanome (radiothérapie), Métastase lymphatique, Radiothérapie adjuvante (), Récidive tumorale locale (), Récidive tumorale locale (radiothérapie), Résultat thérapeutique, Traitement médicamenteux adjuvant, Tumeurs cutanées (), Tumeurs cutanées (radiothérapie), Tumeurs de l'anus (radiothérapie), Tumeurs de la tête et du cou (radiothérapie), Tumeurs du rectum (radiothérapie).
- MESH :
- radiothérapie : Mélanome, Récidive tumorale locale, Tumeurs cutanées, Tumeurs de l'anus, Tumeurs de la tête et du cou, Tumeurs du rectum.
- usage thérapeutique : Antinéoplasiques, Interférons.
- Facteurs de risque, Humains, Lymphadénectomie, Mélanome, Métastase lymphatique, Radiothérapie adjuvante, Récidive tumorale locale, Résultat thérapeutique, Traitement médicamenteux adjuvant, Tumeurs cutanées.
English descriptors
- KwdEn :
- Antineoplastic Agents (therapeutic use), Anus Neoplasms (radiotherapy), Chemotherapy, Adjuvant, Head and Neck Neoplasms (radiotherapy), Humans, Interferons (therapeutic use), Lymph Node Excision, Lymphatic Metastasis, Melanoma (radiotherapy), Melanoma (surgery), Neoplasm Recurrence, Local (radiotherapy), Neoplasm Recurrence, Local (surgery), Radiotherapy, Adjuvant (methods), Rectal Neoplasms (radiotherapy), Risk Factors, Skin Neoplasms (radiotherapy), Skin Neoplasms (surgery), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Interferons.
- methods : Radiotherapy, Adjuvant.
- radiotherapy : Anus Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Recurrence, Local, Rectal Neoplasms, Skin Neoplasms.
- surgery : Melanoma, Neoplasm Recurrence, Local, Skin Neoplasms.
- Chemotherapy, Adjuvant, Humans, Lymph Node Excision, Lymphatic Metastasis, Risk Factors, Treatment Outcome.
Abstract
Although melanoma was historically thought to be radiation resistant, there are limited data to support the use of adjuvant radiation therapy for certain situations at increased risk for locoregional recurrence. High-risk primary tumor features include thickness, ulceration, certain anatomic locations, satellitosis, desmoplastic/neurotropic features, and head and neck mucosal and anorectal melanoma. Lentigo maligna can be effectively treated with either adjuvant or definitive radiation therapy. Some retrospective and prospective randomized studies support the use of adjuvant radiation to improve regional control after lymph node dissection for high-risk nodal metastatic disease. Consensus on the optimal radiation doses and fractionation is lacking.
DOI: 10.1016/j.suc.2014.07.006
PubMed: 25245966
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001302
Links to Exploration step
pubmed:25245966Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The role of radiation therapy in melanoma.</title><author><name sortKey="Oxenberg, Jacqueline" sort="Oxenberg, Jacqueline" uniqKey="Oxenberg J" first="Jacqueline" last="Oxenberg">Jacqueline Oxenberg</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263</wicri:regionArea></affiliation></author><author><name sortKey="Kane, John M" sort="Kane, John M" uniqKey="Kane J" first="John M" last="Kane">John M. Kane</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma-Sarcoma Service, Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. Electronic address: john.kane@roswellpark.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma-Sarcoma Service, Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25245966</idno><idno type="pmid">25245966</idno><idno type="doi">10.1016/j.suc.2014.07.006</idno><idno type="wicri:Area/PubMed/Corpus">001302</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001302</idno><idno type="wicri:Area/PubMed/Curation">001302</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001302</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The role of radiation therapy in melanoma.</title><author><name sortKey="Oxenberg, Jacqueline" sort="Oxenberg, Jacqueline" uniqKey="Oxenberg J" first="Jacqueline" last="Oxenberg">Jacqueline Oxenberg</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263</wicri:regionArea></affiliation></author><author><name sortKey="Kane, John M" sort="Kane, John M" uniqKey="Kane J" first="John M" last="Kane">John M. Kane</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma-Sarcoma Service, Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. Electronic address: john.kane@roswellpark.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma-Sarcoma Service, Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Surgical clinics of North America</title><idno type="eISSN">1558-3171</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>Anus Neoplasms (radiotherapy)</term><term>Chemotherapy, Adjuvant</term><term>Head and Neck Neoplasms (radiotherapy)</term><term>Humans</term><term>Interferons (therapeutic use)</term><term>Lymph Node Excision</term><term>Lymphatic Metastasis</term><term>Melanoma (radiotherapy)</term><term>Melanoma (surgery)</term><term>Neoplasm Recurrence, Local (radiotherapy)</term><term>Neoplasm Recurrence, Local (surgery)</term><term>Radiotherapy, Adjuvant (methods)</term><term>Rectal Neoplasms (radiotherapy)</term><term>Risk Factors</term><term>Skin Neoplasms (radiotherapy)</term><term>Skin Neoplasms (surgery)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (usage thérapeutique)</term><term>Facteurs de risque</term><term>Humains</term><term>Interférons (usage thérapeutique)</term><term>Lymphadénectomie</term><term>Mélanome ()</term><term>Mélanome (radiothérapie)</term><term>Métastase lymphatique</term><term>Radiothérapie adjuvante ()</term><term>Récidive tumorale locale ()</term><term>Récidive tumorale locale (radiothérapie)</term><term>Résultat thérapeutique</term><term>Traitement médicamenteux adjuvant</term><term>Tumeurs cutanées ()</term><term>Tumeurs cutanées (radiothérapie)</term><term>Tumeurs de l'anus (radiothérapie)</term><term>Tumeurs de la tête et du cou (radiothérapie)</term><term>Tumeurs du rectum (radiothérapie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Interferons</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radiotherapy, Adjuvant</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Anus Neoplasms</term><term>Head and Neck Neoplasms</term><term>Melanoma</term><term>Neoplasm Recurrence, Local</term><term>Rectal Neoplasms</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Mélanome</term><term>Récidive tumorale locale</term><term>Tumeurs cutanées</term><term>Tumeurs de l'anus</term><term>Tumeurs de la tête et du cou</term><term>Tumeurs du rectum</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Melanoma</term><term>Neoplasm Recurrence, Local</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Interférons</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Chemotherapy, Adjuvant</term><term>Humans</term><term>Lymph Node Excision</term><term>Lymphatic Metastasis</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term><term>Humains</term><term>Lymphadénectomie</term><term>Mélanome</term><term>Métastase lymphatique</term><term>Radiothérapie adjuvante</term><term>Récidive tumorale locale</term><term>Résultat thérapeutique</term><term>Traitement médicamenteux adjuvant</term><term>Tumeurs cutanées</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although melanoma was historically thought to be radiation resistant, there are limited data to support the use of adjuvant radiation therapy for certain situations at increased risk for locoregional recurrence. High-risk primary tumor features include thickness, ulceration, certain anatomic locations, satellitosis, desmoplastic/neurotropic features, and head and neck mucosal and anorectal melanoma. Lentigo maligna can be effectively treated with either adjuvant or definitive radiation therapy. Some retrospective and prospective randomized studies support the use of adjuvant radiation to improve regional control after lymph node dissection for high-risk nodal metastatic disease. Consensus on the optimal radiation doses and fractionation is lacking.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25245966</PMID><DateCreated><Year>2014</Year><Month>09</Month><Day>23</Day></DateCreated><DateCompleted><Year>2014</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-3171</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Surgical clinics of North America</Title><ISOAbbreviation>Surg. Clin. North Am.</ISOAbbreviation></Journal><ArticleTitle>The role of radiation therapy in melanoma.</ArticleTitle><Pagination><MedlinePgn>1031-47, viii</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.suc.2014.07.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0039-6109(14)00105-4</ELocationID><Abstract><AbstractText>Although melanoma was historically thought to be radiation resistant, there are limited data to support the use of adjuvant radiation therapy for certain situations at increased risk for locoregional recurrence. High-risk primary tumor features include thickness, ulceration, certain anatomic locations, satellitosis, desmoplastic/neurotropic features, and head and neck mucosal and anorectal melanoma. Lentigo maligna can be effectively treated with either adjuvant or definitive radiation therapy. Some retrospective and prospective randomized studies support the use of adjuvant radiation to improve regional control after lymph node dissection for high-risk nodal metastatic disease. Consensus on the optimal radiation doses and fractionation is lacking.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oxenberg</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>John M</ForeName><Initials>JM</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Melanoma-Sarcoma Service, Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. Electronic address: john.kane@roswellpark.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Clin North Am</MedlineTA><NlmUniqueID>0074243</NlmUniqueID><ISSNLinking>0039-6109</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="N">Anus Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Locoregional recurrence</Keyword><Keyword MajorTopicYN="N">Lymphedema</Keyword><Keyword MajorTopicYN="N">Melanoma</Keyword><Keyword MajorTopicYN="N">Nodal metastases</Keyword><Keyword MajorTopicYN="N">Radiation therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25245966</ArticleId><ArticleId IdType="pii">S0039-6109(14)00105-4</ArticleId><ArticleId IdType="doi">10.1016/j.suc.2014.07.006</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001302 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001302 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25245966
|texte= The role of radiation therapy in melanoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25245966" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |